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Synthesis of the Natural Product Descurainolide and Cyclic 
Peptides from Lignin-derived Aromatics 
O. Stephen Ojo†,a Brunello Nardone,a Stefania F. Musolino,a Andrew R. Neal,a Liam Wilson,a Tomas 
Lebl,a Alexandra M. Z. Slawin,a David B. Cordes,a James E. Taylor,a James H. Naismith,a,b Andrew D. 
Smitha and Nicholas J. Westwood*a 
Alternative sources of potential feedstock chemicals are of increasing importance as the availability of oil decreases. The 
biopolymer lignin is viewed as a source of useful mono-aromatic compounds as exemplified by the industrial scale 
production of vanillin from this biomass. Alternative lignin-derived aromatics are available in pure form but to date examples 
of the use of these types of compounds are rare. Here we address this issue by reporting the conversion of an aromatic keto-
alcohol to the anti- and syn-isomers of Descurainolide A. The key step involves a rhodium-catalyzed allylic substitution 
reaction. Enantio-enriched allylic alcohols were generated via an isothiourea-catalyzed kinetic resolution enabling access to 
both the (2R,3R) and (2S,3S) enantiomers of anti-Descurainolide A. In addition we show that the lignin-derived keto-alcohols 
can be converted into unnatural amino acid derivatives of tyrosine. Finally, these amino acids were incorporated into cyclic 
peptide scaffolds through the use of both chemical and an enzyme-mediated macrocylisation. 
Introduction  
Lignin is the second most abundant naturally occurring 
polymer after cellulose.1 At present, only 1-2% of industrially 
produced lignin is converted into commercial products with the 
rest being used as a low value fuel.1 It is clear that applications 
of this renewable material remain underexplored.2 The large 
number of aromatic units present in lignin has inspired methods 
to obtain substituted-phenolic building blocks.3,4 Whilst 
considerable efforts have been channelled into lignin 
depolymerisation,5 many of these processes lead to major 
separation challenges if pure aromatic building blocks are 
required.6,7 An alternative approach investigates the processing 
of native lignins8 through the use of highly selective catalytic 
transformations.9 The advantage of this second approach is that 
it delivers pure monomers albeit with moderate lignin 
conversions. However, this approach will only be viable in an 
industrial context if the pure monomers are useful.10,11 Recently 
we have shown that phenolic monomer 1 can be obtained via 
the selective oxidation of lignin’s β-O-4 units at the benzylic 
alcohol and subsequent C-O bond cleavage (Scheme 1A).11 
Monomer 1 was obtained in pure form from birch lignin. Here, 
in the first part of the work, we report the use of the renewable 
keto-alcohol 1 as a starting point in natural product synthesis, 
specifically, a natural product that contains an electron-rich 
aromatic ring (from 1 via 2 to 3, Scheme 1B). In a second novel 
application of renewable building block 1 and its analogue 4, we 
also report the synthesis of the unnatural tyrosine derivatives 5 
and 6. This section of work culminates in the incorporation of 5 
and 6 into cyclic peptides 7 and 8. 
Scheme 1A: Key steps in the depolymerisation of lignin to give the aromatic 
monomer 1. 1B: Planned application of 1 in the synthesis of a natural product 3 
via 2. 1C: Planned application of 1 and 4 in the formation of an unnatural amino 
acids which are subsequently incorporated into cyclic peptide scaffolds. 
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Descurainolide A (3) is a natural product isolated from the seeds 
of the plant Descurainia Sophia.12 It contains a five-membered 
lactone ring and a 2,6-dimethoxy-phenol ring analogous to that 
in 1.12 The absolute stereochemistry of 3 is currently not 
assigned.12 Whilst no biological activity has been directly 
associated with 3 to date, extracts from the seeds of the D. 
Sophia plant have been used to treat coughs, asthma and 
oedema.12 Uses as a cardiotonic or in cancer therapy have also 
been proposed.12 The synthesis of highly enantio-enriched 
samples of both enantiomers of 3 was viewed as important as it 
should: i) showcase the use of the renewable monomer 1; ii) 
provide both enantiomers of 3 for biological assessment and iii) 
enable the assignment of the absolute configuration of the 
natural product. We envisaged that the construction of the 
lactone ring in 9, a potential precursor of 3, could be achieved 
by diastereoselective iodolactonisation13 of a suitably protected 
γ-olefinic ester 10. Compound 10 could be obtained by 
hydrolysis of one of the esters in 11 followed by decarboxylation 
of the resulting carboxylic acid (Scheme 2). Compound 11 is the 
expected product of a transition metal-catalyzed allylic 
substitution reaction between dimethyl malonate and allylic 
carbonate 12.14 This reaction would enable the selective 
formation of the C1-C2 bond, delivering the required branched 
allylic system.15 Although, our initial study was aimed at racemic 
3, this reaction is known to proceed with retention of 
stereochemistry at the allylic center. This should enable access 
to either enantiomer of 3, provided highly enantio-enriched 
forms of 12 are available (vide infra). The allylic carbonate 12 
could be obtained from 2 (Scheme 1B), which in turn could be 
prepared from our lignin-derived monomer 1. Previously, we 
have shown that 13 can be obtained in one step from 1.12 Whilst 
electron-rich substituents in aromatics of the general structure 
2 are tolerated in the rhodium-catalyzed reaction,16 to the best 
of our knowledge no examples of the use of trialkoxyaryl-




Scheme 2 Our Retrosynthetic Analysis of 3 from keto-alcohol 1. 
In contrast to the relatively small natural product 3, cyclic 
peptides are, arguably, most suitable for targeting large sites.17 
Extended binding pockets or surfaces, for example protein-
protein interactions,18 are often considered “undruggable” by 
small molecules. Natural cyclic peptides, such as cyclosporin A 
(an immunosuppressant drug), possess drug-like cell 
permeability and oral bioavailability that apparently defy the 
physicochemical requirements for bioavailability predicted by 
Lipinski’s Rule of Five.19 More recently, synthetic cyclic peptides 
have been used to investigate the relationship between 
macrocycle structure and cell permeability.20 
Whilst some naturally occurring cyclic peptides contain 
modified amino acids (for example the patellamides21 in which 
serine and threonine residues are processed to oxazoline and 
thiazoline/thiazole rings), synthetic chemistry has enabled a 
number of unnatural amino acids to be built into cyclic peptides. 
Through the production of the tyrosine analogues 5 and 6 from 
our keto-alcohols 1 and 4, cyclic peptides containing these 
unnatural amino acids were prepared. Tyrosine analogues of 
this type are alternatively synthesized by employing tyrosine 
phenol lyases (TPL).22a In addition, unnatural amino acid 
analogues of Tyr, such as those containing aromatic methoxy 
groups are important to help investigate the role of Tyr in 
different enzymes (e. g. cytochrome c oxidase).22b The ability to 
separate diastereomeric cyclic peptides was also required here 
and enabled a detailed NMR study. Overall, through the use of 
two different applications, the utility of the lignin-derived keto-
alcohols 1 and 4 was demonstrated. 
Results and Discussion 
Part 1: Application of 1 to Natural Product Synthesis 
Initially, it was decided to use silyl-protection for the phenol 
in 13. Treatment of 13 with TBSCl, followed by 1,2-reduction of 
the enone using NaBH4 with CeCl3.7H2O23 afforded allylic 
alcohol (±)-2a. To install the C1-C2 bond (11, Scheme 2), allylic 
carbonate (±)-14a was prepared by treating (±)-2a with LiHMDS 
and then methyl chloroformate. The choice of the allylic 
carbonate over allylic acetate was based on the observation 
that oxidative insertion, the first step of the transition metal 
catalyzed allylic substitution, is faster for allylic carbonates than 
for allylic acetates.24 Also, the influence of leaving groups on the 
regioselectivity of the reaction (branched versus linear) has 
previously been studied.25 
 
 
Scheme 3 Synthesis of Allylic Carbonates 14a and 14b: (a) (i) TBSCl, DMAP, Imidazole, 
DCM, rt, 1 h, 90% (ii) PivCl, DMAP, Imidazole, DCM, 1 h, 87% (b) NaBH4, CeCl3.9H2O, 
MeOH, 1 h, 95% for 2a, 91% for 2b (c) Methyl chloroformate, LiHMDS, THF, 1 h, -10 °C, 
15% for 14a, 89% for 14b. See Scheme S1 for more detail. 
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It was found that allylic carbonate (±)-14a was unstable on 
storage and purification on silica giving numerous compounds, 
one of which was the linear isomer 15 (Scheme 3).26,27 It was 
therefore decided to use an electron-withdrawing substituent 
on the phenolic oxygen which led to the preparation of the 
stable pivolate-protected (±)-14b from 13, via alcohol (±)-2b, 
(Scheme 3).28 The exposure of (±)-14b to rhodium-catalyzed 
allylic substitution with dimethyl malonate (5 mol% of 
RhCl(PPh3)3 and 20 mol% of P(OMe)3 in THF at 40 °C provided 
(±)-16 in high yield (87%) as a single regioisomer (Schemes 4, S2 
and Figure S1).29 
 
Scheme 4 Synthesis of anti-(±)-Descurainolide A: (a) NaH, Dimethyl malonate, 
RhCl(PPh3)3 (5 mol%), P(OMe)3 (20 mol%), THF, 40 °C, 1 h, 87% (b) LiCl, H2O, DMSO, 140 
°C, 16 h, 76% (c) I2, MeCN, 0 °C to rt, 46 h, 70% combined yield (d) Pd/C, H2, NaOAc, 
MeOH, rt, 16 h, 86% (e) 2 M HCl/1,4-dioxane (1:1), 100 °C, 12 h, 70%. The thermal 
ellipsoid plot for anti-(±)-3 is also shown at 50% ellipsoid probability.30 
Treatment of purified (±)-16 with LiCl in DMSO/H2O afforded γ-
olefinic ester (±)-17 in 76% yield31 and iodolactonisation using 
I2/MeCN at 0 °C furnished (±)-18 in a anti:syn ratio of 19:1 (Figure 
S2).32 After careful separation, dehalogenation of anti-(±)-18, using 
Pd/H2 and NaOAc in MeOH provided anti-(±)-19 in 86% yield and 
removal of the Piv-group with 2M HCl/ 1,4-dioxane gave anti-(±)-
Descurainolide A (3) in a 62% yield. X-ray crystallographic analysis of 
anti-(±)-3 confirmed the bond connectivity and relative 




Scheme 5 Synthesis of syn-(±)-Descurainolide A: (a) 4 M NaOH, THF/MeOH (1:1), 100 °C, 
92% for (±)-15 and 90% for (±)-17 (b) NaH, MeI, DMF, rt, 1 h, 95% (c) NaH, BnBr, DMF, rt, 
1 h, 83% (d) I2, NaHCO3 (aq), DCM, rt, 12 h, 85% combined yield (e) Pd/C, H2, NaOAc, 
MeOH, rt, 16 h, 62% syn-(±)-3. 
Attempts to tune the iodolactonisation reaction of (±)-17 to enable 
the preparation of sufficient amounts of syn-(±)-18 en route to syn-
(±)-3 proved unsuccessful (Table S1). However, conversion of Piv-
protected ester (±)-17 via (±)-20 and (±)-21 to benzyl protected acid 
(±)-22, and subsequent iodolactonisation using I2 and aqueous 
NaHCO3 provided (±)-23 in a anti:syn ratio of 1:3 (Figure S3) and 85% 
combined yield (Schemes 5 and S3). After careful separation, 
hydrogenolysis of syn-(±)-23 over palladium on carbon gave syn-(±)-
3 in 62% yield. Detailed comparison of the NMR data associated with 
our samples of anti-(±)-3 and syn-(±)-3 with that reported for the 
isolated Descurainolide A12 confirmed that the natural material had 
the proposed relative stereochemistry12 (Table S2). 
      In an attempt to determine the absolute configuration of natural 
anti-3, access to both enantiomers of a protected lignin-derived 
allylic alcohol 2 was required. In this regard, acylative kinetic 
resolution is an attractive strategy as it would allow access to both 
enantiomers from the readily available racemate.33 The Smith group 
has reported that the isothiourea HyperBTM 24 is an effective 
catalyst for the kinetic resolution of challenging aryl-alkenyl alcohols 
in which the catalyst must differentiate between two sp2-hybridized 
substituents during the selectivity-determining acylation step.34 
Moreover, this methodology is particularly effective for alcohols 
bearing electron-rich aryl rings, such as those derived from 
monomers of lignin. 
      To assess the applicability of this method for the preparation of 
enantiomerically enriched anti-3, the selectivity (S=kfast/kslow) for the 
kinetic resolution of a range of protected allylic alcohols 2a-f was 
investigated (Table 1). Both tri- and disubstituted allylic alcohols 2a-
d bearing either O-silyl or O-pivaloyl protecting groups underwent 
highly selective kinetic resolution (S = 29-64) using isobutyric 
anhydride (0.6 eq) and HyperBTM 24 (1 mol%) in the presence of 
iPr2NEt in toluene at -78 °C (Table 1, entries 1-4).34 Lower, but still 
synthetically useful, selectivity was obtained for alcohols 2e and 2f 
bearing O-tosyl and O-triflyl groups, respectively (Table 1, entries 5 
and 6). 
     As the kinetic resolution of alcohol (±)-2b gave the highest 
selectivity, this process was performed on a preparative scale (3.4 
mmol, 1.0 g). In this case, leaving the kinetic resolution to reach 57% 
conversion allowed (S)-2b to be isolated as a single enantiomer in 
37% yield (Scheme 6), with the recovered isobutyrate ester (R)-25b 
(47% yield, 75% ee) readily hydrolysed with 1M KOH to give (R)-2b 
(75% ee). The enantiopurity of (R)-2b was further enhanced through 
a second kinetic resolution using enantiomeric (2R,3S)-HyperBTM 
(ent-24) to acylate selectively the remaining minor enantiomer, 
requiring only 20% conversion to obtain (R)-2b in 92% ee. Overall, 
highly enantiomerically enriched (S)- and (R)-2b could be obtained 
from (±)-2b in a combined 72% yield, demonstrating the powerful 
nature of acylative kinetic resolution. 
     With (R)-2b and (S)-2b in hand, the synthesis of both enantiomers 
of anti-3 was achieved (Schemes 7 and S4). Conversion of (S)-2b into 
(S)-14b enabled the absolute configuration of (S)-14b to be 
confirmed by X-ray analysis (Figure S5). The subsequent Rh(I)-
catalysed allylic substitution reaction was expected to proceed with 
retention of stereochemistry (double inversion) when soft 
nucleophiles (pKa < 22) are employed,15 and with high conservation 
of enantiomeric excess (cee).35 At 40 °C, we observed erosion of ee, 
from 99% (S)-14b to 83% of (R)-16. Perhaps at 40 °C the σ-π-σ 
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isomerisation between the two enantiomers of the π-
allylrhodium(III) complex, which is reported to be slow,15c is slightly 
enhanced in this system. However, at ambient temperature, we 
obtained a high cee (~99%) for both (R)- and (S)-16. 
 
Scheme 6 Preparative kinetic resolution of (±)-2b: (a) (2S,3R)-HyperBTM 24 (1 mol%), 
(iPrCO)2O (0.6 eq), iPr2NEt (0.5 eq), PhMe, –78 °C, 37% for (S)-2b and 47% for (R)-25b; (b) 
1M KOH, MeOH/H2O, rt, quant.; (c) (2R,3S)-HyperBTM (ent-24) (1 mol%), (iPrCO)2O (0.15 
eq), iPr2NEt (0.2 eq), PhMe, –78 °C, 75% for (R)-2b. 
Table 1 Kinetic resolution of allylic alcohols (±)-2a-f 
 
aCalculated by HPLC analysis. bDetermined by HPLC analysis. cCalculated using the 
equations developed by Kagan.36 dProof of the absolute configuration of (S)-2a came 
from X-ray crystallographic analysis (Figure S4). eReaction performed in THF. 
 
     Using the previously established protocols (R)- and (S)-16 were 
converted to anti-(2R,3R)-3 and anti-(2S,3S)-3 respectively (Schemes 
7 and S4 and Table S3). Chiral HPLC analysis of anti-(2S,3S) and anti-
(2R,3R)-3 and analysis of the two compounds by circular dichroism 
(Figure S7) demonstrated that the two samples of 3 were highly 
optically enriched enantiomers of each other. X-ray crystallographic 
analysis of anti-(2R,3R)-3 (Figure S6) confirmed the allylic 
substitution reaction occurred with the precedented retention of 
configuration and the absolute configuration of anti-(2R,3R)-3.15 
     Repeated attempts to obtain a sample of the natural product from 
the group that originally isolated it were unsuccessful. This hindered 
our attempts to assign the absolute configuration of native 
Descuranolide A (3), due to the small values for the optical rotation 
of 3 that we observed and that are reported in the literature (Table 
S3).12 In summary of part 1, the renewable lignin-derived keto-
alcohol 1 was converted to both of the potential diastereomers of 
the natural product 3 enabling confirmation of the relative 
stereochemistry. Assignment of the absolute configuration will 
require reisolation of the natural material due to the low optical 
rotation of 3. 
 
Scheme 7 Synthesis of anti-(2R,3R)- and anti-(2S,3S)-Descurainolide A (3): (a) Methyl 
chloroformate, LiHMDS, THF, 1 h, -10 °C; 95% for R-14b, 74% for S-14b (b) NaH, Dimethyl 
malonate, RhCl(PPh3)3 (5 mol%), P(OMe)3 (20 mol%), THF, 22 °C, 16 h; 79% for S-16, 85% 
for R-16 (c) LiCl, H2O, DMSO, 140 °C, 16 h; 47% for R-17, 55% for S-17 (d) I2, MeCN, 0 °C 
to rt, 48 h; 45% for anti-(2R,3S)-18, 48% for anti-(2S,3R)-18 (e) Pd/C, H2, NaOAc, MeOH, 
rt, 16 h; 52% for anti-(2R,3R)-19, 59% for anti-(2S,3S)-19 (f) 2 M HCl/1,4-dioxane (1:1), 
100 °C, 12 h; 42% for anti-(2S,3S)-3, 61% for anti-(2R,3R)-3. 
Part 2: Application of 1 and 4 to Cyclic Peptide Synthesis 
Having demonstrated that renewable aromatic monomer 1 
could be used as a starting point in natural product synthesis, 
we turned to our second application in the synthesis of 
unnatural amino and cyclic peptides. Both building blocks 1 and 
4 (Scheme 1) were converted to their corresponding triols (±)-
26 and (±)-27 in three synthetic steps (Schemes S5 and S7).37 
 
 
Scheme 8 aReaction Conditions: (a) K2CO3, BnBr, DMF, rt, 3 h (b) 2,2-dimethoxypropane, 
pTSA.H2O (catalytic), DCM; 91% for (±)-28 and 89% for (±)-29 over 2-steps (c)  Pd/C (10% 
wt), H2 gas, NaOAc, MeOH, rt, 12 h (d) Dess-Martin Periodinnane, DCM, rt, 2 h (e) NaClO2, 
NaH2PO4, 2-methyl-2-butene, tBuOH/H2O, rt, 12 h (f) SOCl2, DCM then EtOH; 78% for (±)-
30 and 68% for (±)-31 over 4-steps (g) pTSA.H2O, 77% for (±)-32 and 69% for (±)-33. 
The primary alcohols in (±)-26 and (±)-27 were selectively 
protected as benzyl ethers, and the remaining diols were 
protected as acetals to give (±)-28 and (±)-29 (Scheme 8). After 
entry R R1  
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careful separation, the major diastereoisomer (relative 
stereochemistry unassigned) of (±)-28 and (±)-29 respectively 
were subjected to debenzylation,37a Dess-Martin oxidation, 37b 
Pinnick oxidation37c and esterification37d to furnish (±)-30 and 
(±)-31 in 78% and 68% over four steps. Subsequent removal of 
the acetal groups using pTSA.H2O provided diol-esters (±)-32 
and (±)-33 in 77% and 69%, respectively.38 
Exposure of (±)-32 and (±)-33 to Et3SiH and BF3.OEt2 in DCM 
at -78 °C for 2 h gave α-hydroxy esters (±)-34 and (±)-35 in 
moderate yields (Scheme 9).39 This benzylic deoxygenation 
protocol was found to be very substrate dependent and this was 
the main factor that defined the route taken from 1 and 4 to 5 
and 6 respectively. After conversion of the remaining alcohol in 
(±)-34 and (±)-35 to the corresponding tosylate using LiHMDS 
and TsCl, subsequent reaction with NaN3 in DMF gave azido-
esters (±)-36 and (±)-37 in 88% and 78% yields respectively. The 
reduction of the azide group was accomplished using Pd/C (10 
wt%) in ethyl acetate under an atmosphere of H2 gas. The 
treatment of the resulting crude amines with FmocCl then gave 
N-Fmoc protected amino esters (±)-38 and (±)-39 in 93% and 
98% yields respectively. Hydrolysis of the ester and 
deprotection of the TBS-silyl ether occurred when (±)-38 and 
(±)-39 were refluxed in 2 M HCl:1,4-dioxane (1:1) for 12 h, 
furnishing N-Fmoc protected amino acids (±)-5 in 72% yield and 
(±)-6 in 76% yield.40 
 
 
Scheme 9 (a) Et3SiH, BF3.OEt2, DCM, -78 °C, 2 h, 56% for (±)-34 and 66% for (±)-35 (b) 
LiHMDS, TsCl, THF, rt, 1 h, 75% and 60% (c) NaN3, DMF, rt, 3 h, 88% for (±)-36 and 78% 
for (±)-37 (d) (i) Pd/C (10% wt), H2, EtOAc, 1 h (ii) FmocCl, THF, 1 h, 93% for (±)-38 and 
98% for (±)-39 (e) 2 M HCl:1,4-dioxane (1:1), 100 °C, 12 h, 72% for (±)-5 and 76% for (±)-
6. 
At this stage, the application of the S- and G- functionalized 
lignin phenolic monomers 1 and 4 in the synthesis of N-Fmoc 
protected unnatural amino acids has been demonstrated. In 
addition, the treatment of the crude amino-ester (±)-40 
(Scheme 10) with LiOH in THF:H2O (1:1) for 1 h at room 
temperature gave the amino acid (±)-41, which was 
recrystallized to provide suitable quality crystals.30 This analysis 
confirmed the assigned structure of (±)-41. 
 
Scheme 10 (a) Pd/C (10% wt), H2, EtOAc, 1 h; (b) LiOH, THF:H2O (1:1), rt, 1 h, 88% crude 
yield. The thermal ellipsoid plot for anti-(±)-41 is shown at 50% ellipsoid probability.25 
The linear peptides 42 and 43 (amino acid sequence: 
AXIGFPVG where X = (±)-5 or (±)-6 after removal of the Fmoc 
group respectively) were synthesised using a solid-phase 
peptide synthesis (SPPS) strategy. A preloaded Gly-2-
chlorotrityl chloride resin was used to couple N-Fmoc protected 
amino acids (±)-5 and (±)-6 with seven other naturally occurring 
amino acids (Scheme 11).41,42,43 After washing and swelling of 
the resin, suitably protected valine (V), proline (P), 
phenylalanine (F), glycine (G) and isoleucine (I) were 
successively double coupled using a 4-fold excess of amino acid 
for 20 mins at 75 °C making use of (i) DIC (0.5 M in DMF), Oxyma 
(1 M in DMF) and (ii) HBTU (0.5 M in DMF), DIEA (2 M in DMF) 
coupling reagent protocols. Prior to adding the next amino acid, 
the peptide-bound resin was Fmoc-deprotected with a solution 
of 20% piperidine in DMF for 10 min.  
 
 
Scheme 11 Synthesis of cyclic peptide precursors 42 and 43. (a) suitably protected 
natural amino acid or (±)-5 or (±)-6, DIC (0.5 M in DMF), Oxyma (1 M in DMF) and/or 
HBTU (0.5 M in DMF), DIEA (2 M in DMF); (b) (i) 20% HFIP in DCM, 30 min and (ii) 94% 
trifluoroacetic acid, 4% H2O, 2% triisopropylsilane, 2 hrs. 
The unnatural amino acid (±)-5 or (±)-6 was then single 
coupled for 30 minutes, followed by Fmoc removal and double 
coupling of the terminal alanine residue. The final Fmoc-
deprotection was carried out with a solution of 50% piperidine 
in DMF for 3 minutes and the resin was washed extensively. The 
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linear peptide was cleaved from the resin using a solution of 
20% HFIP (hexafluoro isopropanol) in DCM followed by 94% 
trifluoroacetic acid, 4% H2O, 2% triisopropylsilane. Peptides 42 
and 43 (as 1:1 mixtures of diastereoisomers) were isolated in 
52% and 45% yield respectively. The chemical cyclisation43 of 
the linear peptides 42 (dr 1:1, X derived from (±)-5) and 43 (dr 
1:1, X derived from (±)-6) was achieved using PyBOP and DIEA 
to give cyclic peptides 7 and 8 respectively, both as 1:1 mixture 
of diastereoisomers (Scheme 12). The use of HATU as the 
coupling reagent led to formation of the cycle that had also 
been modified by the coupling reagent, presumably through 
reaction of the unprotected phenolic OH.44 No major 
differences in the rate of cyclisation of the diastereomeric linear 
peptides was observed. The two diastereoisomers of 7 and 8 
were separated by semi-preparative RP-HPLC. 
 
 
Scheme 12 Synthesis of cyclic peptides 2(S)-7, 2(R)-7, 2(S)-8 and 2(R)-8 (a) (i) PyBOP, 
DIEA, DMF (ii) RP-HPLC purification enabled separation of diastereomers. 
Interestingly, detailed 1D and 2D NMR analysis of the cyclic 
peptides showed that each diastereoisomer of 7 and 8 
consisted of two main conformers in varying ratios (Figures 1, 
S14, S23, S30 and S36). The absolute stereochemistry of the two 
diastereomers of 7 were assigned based by comparison of the 
1H-15N HSQC spectra with the spectrum of a related cyclic 
peptide (S)-44 prepared using enantiomeric pure ˪-(S)-Tyrosine 
(Y) (Figure 1). The 1H-15N HSQC analysis of (S)-44 (Figure 1C) was 
very similar to that of one of the two diastereomers (Figure 1A) 
and very different from the analysis of the second diastereomer 
(Figure 1B), For example, the signal corresponding to the NH of 
the tyrosine residue in 2(S)-44 (8.01/111.7 ppm, labeled as Yb in 
Figure 1C) was similar in chemical shift to the signal for the 
analogous NH for the unnatural amino acid residue derived 
from (±)-5 in what was assigned as the 2(S)-7 diastereomer 
(8.02/111.8 ppm, labeled as Xb in Figure 1A), whereas, the 
analogous signal in the assigned 2(R)-7 diastereomer was found 
at 8.07/124.7 ppm (Figure 1B). An analogous situation was 
observed for the two separated diastereomers of cyclic peptide 
8 enabling one of them to be assigned as the 2(S)-8 
diastereomer due to similarity of its 1H-15N HSQC analysis to 
that of (S)-44 (Tables S8-S11). 
 
Figure 1: Assignment of the stereochemistry of the two diastereomers of cyclic peptide 
7 by comparison with the 1H-15N HSQC analysis of 2(S)-44. 
In the final part of this study, the enzyme-mediated 
cyclisation of linear peptide 42 was explored using the 
macrocyclase enzyme PatGmac.45 Previous reports have shown 
the effectiveness of this enzyme for the cyclization of a wide 
range of linear peptides that contain natural and unnatural 
amino acids.46 Based on the understanding of the mechanism of 
PatGmac,45 the precursor linear peptide must have a C-terminal 
amino acid motif (AYD) that is recognised by the enzyme. 
Therefore, modified linear peptide 45 (VGAXIGFPAYD where X 
was derived from (±)-5) was prepared and converted to the 
diastereomeric cyclic peptides 2(S)-7 and 2(R)-7. The two 
diastereomers were formed in an approximately 1:1 (Scheme 
13, Figures S21 and S22), implying that the rate of 
macrocyclisation by PatGmac was not influenced by the 
stereochemistry at the unnatural amino acid stereogenic center 
in this system. 
 
 
Scheme 13 (a) PatGmac enzyme, 20 mM bicine buffer, 500 mM NaCl, and 5% DMSO 
solution, pH = 8.1 and incubated at 37 °C (without shaking). No difference in the rates of 
formation of the two diastereomeric cyclic peptides was observed (Figure S21). 
Conclusions 
In conclusion, we have synthesized the (2R,3R)- and (2S,3S)- 
enantiomers of anti-Descurainolide A 3 from a lignin-derived, 
keto-alcohol 1. The allylic alcohol (±)-2b was converted into 
highly enantio-enriched samples of both enantiomers using the 
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organocatalyst HyperBTM 24. The rhodium catalyzed allylic 
substitution reaction proceeded with high conservation of 
enantiomeric excess and enabled the key C-C bond formation 
step. In addition, we have converted the lignin-derived phenolic 
monomers 1 and 4 into N-Fmoc protected unnatural amino 
acids 5 and 6, respectively. These unnatural amino acids were 
incorporated into cyclic peptides 7 and 8. Overall this work has 
showcased the applicability of these phenolic monomers in 
differing areas of synthetic organic chemistry. 
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